1 / 44

Drugs and The Kidney

Drugs & The Kidney. Drugs and The Kidney. Dr. Shahrzad Shahidi. Dr. Shahrzad Shahidi. Introduction . The heart pumps approximately 25% of CO into the kidneys Any drug in the blood will eventually reach the highly vascularized kidneys May potentially cause drug-induced renal failure

chandler
Download Presentation

Drugs and The Kidney

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drugs & The Kidney Drugs and The Kidney Dr. Shahrzad Shahidi Dr. Shahrzad Shahidi

  2. Introduction • The heart pumps approximately 25% of CO into the kidneys • Any drug in the blood will eventually reach the highly vascularized kidneys • May potentially cause drug-induced renal failure • The drug may be filtered or secreted into the lumen of the renal tubules • The concentrated drug exposes the kidney tissue to far greater drug concentration per surface area

  3. Clinical Presentation • Drug-induced renal disease can mimic renal disease from other causes, such as autoimmune disease & infection • A thorough PEx& medical Hx should be performed • Increase in serum Cr & BUN • Additional urine tests: Pr excretion, Cr concentration, osmolality or Na excretion • A thorough & accurate review of all medications, including all prescription, over-the-counter & herbal medications • Importance of dose & duration of exposure • Rule out all other causes of kidney failure

  4. Pseudo Renal Failure • ↑BUN due to protein catabolism • Steroids, tetracyclines • ↑SCr due to competitive inhibition of cr secretion • Trimethoprim, Cimetidine • Trimethoprim • 15-35% rise SCr fully expressed after 3 days • More sig in pts with pre-existing renal dysfunction • Can occur with normal doses • Completely reversible when drug is discontinued

  5. Mechanisms of nephrotoxin-inducedARF • Direct nephrotoxicity • Tubuloepithelial injury • ATN (e.g.,aminoglycosides) • Osmotic nephrosis (e.g., hypertonic solutions, IV IG) • Interstitial nephritis • Acute allergic interstitial nephritis (e.g., penicillins) • Chronic interstitial nephritis (e.g., calcineurin inhibitors) • Papillary necrosis (e.g., NSAIDs) • Glomerular disease • Glomerulonephritis (e.g., gold, penicillamine, ACE inhibitors) • Renal vasculitis (e.g., hydralazine) • Obstructive uropathy • Crystalline nephropathy (e.g., acyclovir, indinavir) • Indirect nephrotoxicity • Decreases intrarenal blood flow (e.g., ACE inhibitors, NSAIDs)

  6. Patterns of Drug-induced Lesions Tubulointerstitium • Acute tubular injury - Osmotic nephrosis - Nephrocalcinosis - Crystal NP • Acute interstitial nephritis • Chronic tubulointer- stitial nephropathy • Glomeruli • Minimal change disease • Focal segmental glomerulosclerosis • Membranous GN • Crescentic GN • Thrombotic micro- angiopathy • Blood vessels • Hyalinosis • Thrombotic micro-angiopathy • Vasculitis

  7. Virostatics Phenytoin Sulfasalazine Quinolones Bisphosphonates Bisphosphonates Tamoxifen Interferon Sirolimus Cisplatin Quinine Cisplatin CNI Hydralazin Lithium COX2-I NSAID HES Thiazids Lithium Captopril Barbiturates Clopidogrel Rifampicin ACE-I NSAID CNI CNI Antibiotics Diazepam Patterns of Drug-induced Lesions Tubulointerstitium Acute interstitial nephritis Chronic tubulointer- stitial nephropathy Acute tubular injury - Osmotic nephrosis - Nephrocalcinosis - Chrystal NP Glomeruli Minimal change disease Focal segmental glomerulosclerosis Membranous GN Crescentic GN Thrombotic micro- angiopathy Blood vessels Hyalinosis Thrombotic micro- angiopathy Vasculitis Ranitidin

  8. Case PP: Female , 50 y CC: Fatigue since 1 wk ago PI: Nocturia, Polyuria 2 wks PH:Sinusitis 3 wks ago, treated with Amoxicilline 500 mg 3 tab/d for 2 wks, HTN 5 yrs FH: HTN in her mother, DM in her brother PE: BP: 90/60, PR: 86, Pallor, dry mouth & skin. Amoxicilline Nocturia, Polyuria Fatigue

  9. Case • Hb: 10 g/L • FBS: 80 mg/dl • BUN: 60 mg/dl • Cr: 4 mg/dl • Na: 124 meq/L • K: 6 meq/L • UA: 9 mg/dl • U/A: • SG 1.007 • Pr + • Glu + • RBC 6-8/HPF • WBC 10-15/HPF • WBC cast 0-1/LPF • U/C: Neg

  10. Based on Experimental AIN www.nature.com/ki/journal

  11. Pre-renal causes • Vasoconstriction • Contrast agents • Amphotericin, noradrenalin, immunosuppressive agents such as tacrolimus & cyclosporine • Iodinated contrast media, in particular, have been shown to inhibit the synthesis of nitric oxide in renal artery smooth muscle

  12. Radiocontrast Agents • Ionic vs. Nonionic • High (1500-1800) Low (600-850) Iso-osmolal (~ 290 mOsm/kg))

  13. Radiocontrast Agents • Pathogenesis: • Renal Vasoconstriction (Adenosine, Endothelin) • Tubular Injury Oxidative stress induced damage

  14. Radiocontrast Agents • Risk Factors: • Underlying renal disease (Cr >1.5mg/dl) • Diabetic nephropathy, HF, Hypovolemia • Multiple Myeloma • Dose (lower doses safer but not necessarily safe)

  15. Radiocontrast Agents • Incidence • Negligible when renal function is normal (even if diabetic) • 4 -11% in patients with Cr 1.5 – 4.0 mg/dL • 50% if Cr > 4.0 mg/dL and in diabetic nephropathy • Diagnosis • Characteristic rise in plasma Cr following administration of the agent

  16. Radiocontrast Agents Prevention: • Use of alternative diagnostic procedures in high risk patients • Avoidance of volume depletion or other nephrotoxins • Low-doses of low- or iso-somolar agent • IV saline

  17. Case • 65 year old male with H/o HTN, ventricular arrythmias controlled on Amiodarone, OA on NSAIDs. presents with puffiness on face on waking up. Has bilateral pitting edema. • U/A: 3+ pr, RBC 3-5/HPF, WBC 15-20/HPF • 24 h urine pr : 4 g • BUN: 80 mg/dl , Cr: 5 mg/dl, Serum Albumin : 2.8 g/dl, TSH : Nr • The most likely Diagnosis? A) Amiodarone induced hypothyroidism B) RPGN C) NSAIDs induced nephrotic syndrom & interstitial nephritis • The most likely Management & Follow up?

  18. Nephrotic syndrome • Abnormal amounts of Pr in the urine • Drugs : NSAIDs, penicillamine & gold,…. • Damage the glomerulus & alter the ability of the glomerulus to prevent Pr from being filtered • Stopping the drug may resolve the damage to the glomerulus

  19. Nonsteroidal Anti-InflammatoryDrugs (NSAIDs) Chemical Structure Generic Name Acetic acids: Diclofenac, Indomethacin, Sulindac, Fenamates: Meclofenamate, Mefenamic acid Napthylalkanones: Nabumetone Oxicams: Meloxicam, Piroxicam Propionic acids: Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin Pyranocaboxylic acid: Etodolac Pyrrolizine carboxylic acid: Ketorolac Selective COX-2 inhibitors: Celecoxib, Rofecoxib

  20. NSAIDs • Hemodynamically- Induced ARF • Acute Interstitial Nephropathy + Proteinuria • Papillary necrosis & CRF(Analgesic nephropathy) • Salt & water retention: Hyperkalemia, HTN

  21. NSAIDs • Acute Interstitial Nephropathy + Proteinuria • Acute interstitial nephritis • Minimal-change glomerular disease • Proteinuria • Prognosis good after discontinuation of therapy; Corticosteroids ?

  22. NSAIDs • Analgesic nephropathy (Chronic Interstitial Nephritis & Papillary necrosis ) • Single vs. combined analgesics • Dose dependent (at least 1 kg) • Patients with history of depended behaviors • Slowly progressive ; Asymptomatic, sometimes hematuria, flank pain, or urinary infections. • Being responsible for 1% to 3% of ESRD cases

  23. Analgesic Nephropathy Papillary necrosis

  24. Analgesic Nephropathy Papillary necrosis

  25. NSAIDs/COX II Inhibitors • Physician would like to switch previous patient from Naproxen to Celecoxib • Are Cox II inhibitors less likely to cause ARF compared to NSAIDs?

  26. NSAIDs/COXibs • Use with caution in CKD (grade 3 or greater) • Inhibit renal vasodilatory prostaglandins E2 & I2 • Produced by COX-2 • Reversible reduction in GFR • Higher risk if intravascular volume depletion • Management: D/C drug, use alternate analgesia • HTN • Edema, sodium and water retention • Mean increase SBP 5 mm Hg • HyperkalemiaRisk • Blunting of PG-mediated renin release

  27. Osmotic nephrosis • A morphological pattern with vacuolization & swelling of the renal proximal tubular cells. • The term refers to a nonspecific histopathologic finding rather than defining a specific entity. • It has a broad clinical spectrum that includes AKI & CKD in rare cases. • High doses of mannitol, soucrose-containing IVIg, contrast dye , dextrans & starches are nephrotoxic • Mechanism: uptake of these large molecules by pinocytosis into the proximal tubule cells.

  28. Post-renal failure • Usually results from a mechanical barrier to moving urine from the collecting tubules into the bladder • Mechanical obstruction : • Bladder retention (in BPH, Neurogenic bladder) • Kidney stones • Drugs that precipitate in the kidney (acyclovir, ganciclovir)

  29. DRUGS OF ABUSE • Cocaine & heroin • Cocaine use can cause renal artery thrombosis (clotting), severe HTN & interstitial nephritis • Long-term cocaine use can lead to CRF • Tobacco use increase the progression rate of CKD • Long-term tobacco use also increases the risk of kidney cancer

  30. Crystal-Induced ARF • Acyclovir (antiviral agent ) • Indinavir (antiretroviral agent, protease inhibitor) • Methotrexate (antineoplastic agent, antimetabolite) • Sulfonamide antibiotics • Triamterene

  31. Crystal-Induced ARF Sulfonamide crystals Indinavir sulfate urinary crystals Gagnon et al. 1998, Ann Intern Med 128-321

  32. Case • 52 yo male with Type 2 DM • Baseline cr 1.8 mg/dl; BP 145/90 • Enalapril 10 mg daily started & 2 weeks later: BP 135/80 • Serum cr 2.2 mg/dl

  33. Optimal Use of ACEI/ARB • Cr ↑ 1.8 to 2.2 mg/dl in 2 wks • Accept 20-30% increase in serum crwithin 1-2 months of initiation • In fact, this could be an indication that the drugs are exerting their desired actions to help preserve renal function • Check serum cr 1-2 wks after initiation, then in 2-4 wks • If > 30% change, decrease ACEI/ARB dose by 50% & repeat Ser Cr in 4 wks (exclude hypovolemia/NSAIDs, etc) • If > 50% rise in Ser Cr – rule out RAS • Repeat serum crin this patient in 1-2 wks to ensure it has stabilized

  34. Case • 82 yo female with osteoarthritis • Admitted to hospital for CAP & dehydration • Meds: Losartan 100mg daily + Naproxen 250mg BID • Cr 3 mg/dl

  35. Optimal Use of ACEI/ARB • Cr on admission 3 mg/dl in patient with CAP & dehydration • Discontinue NSAID & hold ARB until infection treated & patient is rehydrated/cr reduced • Resume ARB & monitor serum cr

  36. Causes of AKI after Initiation ofTherapy with ACE Inhibitor or ARB • BP insufficient for adequate renal perfusion • Poor cardiac output • Low systemic vascular resistance (e.g., as in sepsis) • Volume depletion (GI loss, excess diuretic use, …) • Presence of renal vascular disease* • Bilateral renal artery stenosis • Stenosis of dominant or single kidney • Afferent arteriolar narrowing (caused by HTN, cyclo..) • Diffuse atherosclerosis in smaller renal vessels • Vasoconstrictor agents (NSAIDs, cyclosporine)

  37. Prevention: General Rules • Be aware of nephrotoxic potential of specific drugs • Identify patients at risk • Be aware of increased risk in elderly • Asses the benefit/risk ratio for Rx of potentially nephrotoxicdrug • Monitor the RFT if necessary

  38. Prevention: General Rules (Cont’d) • Avoid dehydration • Limit dose & duration of treatment • Adjust the dose based on changes in GFR • Avoid a combination of potentially nephrotoxic drugs

  39. Conclusion • Many drugs cause AKI • Increase the risk of drug-induced AKI: • Age (particularly over 65 years) • Pre-existing renal impairment • Comorbiditiessuch as DM, HF, liver cirrhosis • Hypovolaemia • Addressing potential risk factors • Understanding of the mechanisms of nephrotoxicity involved

More Related